Wave Life Sciences Ltd. (NASDAQ:WVE) announced the approval of its first clinical trial application for the RestorAATion-2 trial of WVE-006, aimed at treating alpha-1 antitrypsin deficiency (AATD). WVE-006, a first-in-class RNA editing oligonucleotide, does not use a lipid nanoparticle delivery system and is subcutaneously administered. The trial will evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in individuals with AATD. GSK holds the exclusive global license for WVE-006, with development and commercialization responsibilities transferring to GSK after the completion of the RestorAATion-2 study. Wave Life Sciences is also advancing its RNA editing pipeline across various targets.